User experiences with Fridays for weight loss injections
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Fridays is a telehealth weight‑loss provider that offers weekly injectable GLP‑1/GIP options (compounded semaglutide and tirzepatide) alongside coaching; the company reports average cohort losses of 9.75 lbs in month one and 15.28% body weight at 12 months for heavier enrollees [1]. User reviews praise rapid and sustained weight loss—some reporting tens of pounds lost—and highlight strong clinical follow‑up and coaching, while watchdog reporting and FDA notices about compounded products raise safety and dosing‑error concerns that patients should weigh [2] [3] [4].
1. What patients say: convenience, coaching and large weight drops
Many customer reviews and comparison sites emphasize convenience, robust coaching and significant weight loss. Trustpilot entries include firsthand statements of 40–50+ lb losses and faster short‑term reductions after joining Fridays [2]. Comparison pieces and reviews note that Fridays’ strength is its “proactive care team, detailed follow‑up calls, and educational resources” and that users value ongoing dose optimization and behavioral support tied to medication [3] [5].
2. What Fridays’ data claims: short‑ and long‑term averages
Fridays posts patient‑cohort figures on its site showing an average 9.75‑lb loss in the first month for people starting above 175 lbs and a 15.28% average body‑weight reduction at 12 months in a separate cohort [1]. The company couples those outcomes with a model that pairs GLP‑1/GIP medications and coaching, and it markets month‑to‑month subscriptions with options for prescription fills via telehealth visits [1] [6].
3. Medications offered: compounded vs. brand‑name choices
Fridays provides both compounded versions of semaglutide and tirzepatide and says it can access name‑brand drugs where appropriate. The platform explicitly notes that compounded medications are produced in FDA‑registered facilities but are not FDA‑approved products, and clinicians retain discretion to prescribe or decline them [7] [6] [8]. Review coverage and buyer guides repeatedly point out Fridays’ emphasis on compounded GLP‑1s as a more accessible cost option [7] [5].
4. Safety and regulatory cautions around compounded GLP‑1s
Independent reviews and consumer‑safety reporting flag risks tied to compounded injectable GLP‑1s: the FDA has received reports of dosing errors with compounded semaglutide that produced adverse events including vomiting, abdominal pain, fainting, migraine and acute pancreatitis [4]. Fridays’ FAQ acknowledges that compounded products “have not been evaluated by the FDA for safety, efficacy, or quality,” underscoring a regulatory distinction patients should understand [6] [8].
5. Costs, access and the telehealth trade‑offs
Fridays markets itself as lower‑cost and more supportive than some competitors; pricing materials highlight value from integrated coaching and flexible telehealth access [6] [5]. Third‑party comparisons contrast Fridays’ hands‑on model with quicker, lower‑touch providers; those seeking rapid prescription turnaround might prefer other services, while people wanting dose adjustments and behavioral support may favor Fridays [3].
6. Where reporting disagrees or is unclear
Some outlets praise Fridays’ clarity and support, while others say the site is confusing about which medications and insurance options are available and question features like “oral tirzepatide” that appear on marketing but are not actually provided [9] [10]. The company’s own materials and third‑party reviews conflict on availability of brand versus compounded supplies in every state; Woman’s World cites company statements about near‑nationwide availability but also notes complexity around prescription types [10] [1].
7. Practical advice for prospective users
Available sources recommend verifying that your prescriber and pharmacy are licensed, asking where compounded drugs are made, and discussing known risks—including the FDA’s reports about dosing errors—before beginning therapy [4] [8]. Independent comparisons suggest deciding whether you value intensive coaching and dose optimization (Fridays’ selling point) versus a faster onboarding or lower up‑front price from other telehealth vendors [3] [5].
Limitations: reporting here relies on Fridays’ published cohort data, customer reviews and third‑party reviews; clinical trial efficacy and head‑to‑head safety data for specific compounded preparations are not provided in these sources, and FDA evaluations of brand‑name GLP‑1s are not summarized in the supplied material (not found in current reporting).